Tip: Try a valid symbol or a specific company name for relevant results This Dividend Stock Is Beating the Market in 2026 and Yields 2.36% The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link.
Prices displayed are informational. Merck (MRK) was at the center of a major cancer-treatment update in August. Specifically, the drugmaker and Moderna (MRNA) said their personalized mRNA cancer therapy, intismeran autogene, delivered positive results in a Phase 3 study involving 1,137 patients with high-risk melanoma.
Used with Keytruda, the treatment reduced the risk of cancer returning or causing death and improved distant metastasis-free survival compared with Keytruda alone. Merck shares jumped 11% on the news. That was a big move for the stock, which had posted only five single-day gains of more than 5% over the past year.
The news added to an already strong run for Merck. Currently, MRK stock is up 36% year-to-date (YTD), ahead of the Nasdaq Composite's ($NASX) 12% gain over the same period. The company is also paying investors to wait for the longer-term potential of its cancer pipeline.
Merck declared a quarterly dividend of $0.85 per share, payable on Oct. 7 to shareholders of record on Sept. 15. That works out to about $3.40 per share annually and gives the stock a yield of about 2.36%. Can Merck keep delivering both share-price gains and dividend income heading into 2027?
Let's take a closer look. Merck sells prescription drugs, vaccines, and animal-health products. Its biggest product is Keytruda, a leading cancer treatment that remains the main driver of its oncology business.
Extract — continue reading at the source.
